🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06334562
Recruiting Not applicable

The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery

NCT06334562 · tracked via the Priya Life Science China tracker
Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Not applicable
Started
2024-06-01
Last updated
2025-02-17

Condition(s) studied

Neuromuscular Blockade

Investigational drug(s) / intervention(s)

SUGAMMADEX SODIUM 100 Mg in 1 mLNeostigmine

SUGAMMADEX SODIUM 100 Mg in 1 mL: The dose of Sugammadex Sodium 100 Mg in 1 mL is 2mg/kg

Neostigmine: Neostigmine is 50 μg/kg

Study summary

This study aims to compare the use of sugammadex (domestic) and neostigmine for antagonism after thoracic surgery, and observe the effect of sugammadex (domestic) on neuromuscular blockade antagonism after thoracic surgery, in order to provide a basis for optimizing the use of muscle relaxants and their antagonists during anesthesia.

Eligibility

Sex
ALL
Min age
19 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Patients who undergo elective lung surgery under general anesthesia and require endotracheal intubation; 2. Age\>18 years old, gender not limited; 3. American Society of Anesthesiologists ASA Level I-III; 4. Use rocuronium bromide for neuromuscular blockade; 5. The patient voluntarily participated in the trial. Exclusion Criteria: 1. The patient explicitly refused to participate in this trial; 2. Family history of malignant hyperthermia, patients with allergies to sodium sulbactam, neostigmine ingredients and their excipients, and patients with allergies to drugs used during general anesthesia; 3. Patients with tracheal malformations or suspected difficult airways, coagulation dysfunction, severe liver and kidney dysfunction, and severe lung disease; 4. Patients who are not extubated and sent to the ward or ICU after surgery; 5. The researchers believe that patients with any other unfavorable factors to participate in this trial.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Fourth Affiliated Hospital of Zhejiang University School of Medicine Yiwu Zhejiang Recruiting

More The Fourth Affiliated Hospital of Zhejiang University School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06334562 on ClinicalTrials.gov ↗ ← All trials in China